These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22417012)

  • 1. An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults.
    Talaat KR; Karron RA; Liang PH; McMahon BA; Luke CJ; Thumar B; Chen GL; Min JY; Lamirande EW; Jin H; Coelingh KL; Kemble GW; Subbarao K
    Influenza Other Respir Viruses; 2013 Jan; 7(1):66-73. PubMed ID: 22417012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults.
    Talaat KR; Karron RA; Callahan KA; Luke CJ; DiLorenzo SC; Chen GL; Lamirande EW; Jin H; Coelingh KL; Murphy BR; Kemble G; Subbarao K
    Vaccine; 2009 Jun; 27(28):3744-53. PubMed ID: 19464558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults.
    Talaat KR; Karron RA; Luke CJ; Thumar B; McMahon BA; Chen GL; Lamirande EW; Jin H; Coelingh KL; Kemble G; Subbarao K
    Vaccine; 2011 Apr; 29(17):3144-8. PubMed ID: 21377509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.
    Karron RA; Talaat K; Luke C; Callahan K; Thumar B; Dilorenzo S; McAuliffe J; Schappell E; Suguitan A; Mills K; Chen G; Lamirande E; Coelingh K; Jin H; Murphy BR; Kemble G; Subbarao K
    Vaccine; 2009 Aug; 27(36):4953-60. PubMed ID: 19540952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses.
    Kiseleva I; Dubrovina I; Fedorova E; Larionova N; Isakova-Sivak I; Bazhenova E; Pisareva M; Kuznetsova V; Flores J; Rudenko L
    Vaccine; 2015 Dec; 33(49):7008-14. PubMed ID: 26432909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
    Pitisuttithum P; Boonnak K; Chamnanchanunt S; Puthavathana P; Luvira V; Lerdsamran H; Kaewkungwal J; Lawpoolsri S; Thanachartwet V; Silachamroon U; Masamae W; Schuetz A; Wirachwong P; Thirapakpoomanunt S; Rudenko L; Sparrow E; Friede M; Kieny MP
    Lancet Infect Dis; 2017 Aug; 17(8):833-842. PubMed ID: 28533093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers.
    Isakova-Sivak I; Stukova M; Erofeeva M; Naykhin A; Donina S; Petukhova G; Kuznetsova V; Kiseleva I; Smolonogina T; Dubrovina I; Pisareva M; Nikiforova A; Power M; Flores J; Rudenko L
    Hum Vaccin Immunother; 2015; 11(4):970-82. PubMed ID: 25831405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials).
    Rudenko L; Desheva J; Korovkin S; Mironov A; Rekstin A; Grigorieva E; Donina S; Gambaryan A; Katlinsky A
    Influenza Other Respir Viruses; 2008 Nov; 2(6):203-9. PubMed ID: 19453396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.
    King JC; Fast PE; Zangwill KM; Weinberg GA; Wolff M; Yan L; Newman F; Belshe RB; Kovacs A; Deville JG; Jelonek M;
    Pediatr Infect Dis J; 2001 Dec; 20(12):1124-31. PubMed ID: 11740317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus.
    Smith A; Rodriguez L; El Ghouayel M; Nogales A; Chamberlain JM; Sortino K; Reilly E; Feng C; Topham DJ; Martínez-Sobrido L; Dewhurst S
    J Virol; 2020 Jan; 94(4):. PubMed ID: 31748399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.
    Karron RA; Callahan K; Luke C; Thumar B; McAuliffe J; Schappell E; Joseph T; Coelingh K; Jin H; Kemble G; Murphy BR; Subbarao K
    J Infect Dis; 2009 Mar; 199(5):711-6. PubMed ID: 19210163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine.
    Rudenko L; Kiseleva I; Naykhin AN; Erofeeva M; Stukova M; Donina S; Petukhova G; Pisareva M; Krivitskaya V; Grudinin M; Buzitskaya Z; Isakova-Sivak I; Kuznetsova S; Larionova N; Desheva J; Dubrovina I; Nikiforova A; Victor JC; Neuzil K; Flores J; Tsvetnitsky V; Kiselev O
    PLoS One; 2014; 9(2):e87962. PubMed ID: 24533064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.
    Rudenko L; Kiseleva I; Stukova M; Erofeeva M; Naykhin A; Donina S; Larionova N; Pisareva M; Krivitskaya V; Flores J;
    Vaccine; 2015 Sep; 33(39):5110-7. PubMed ID: 26296497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replication of live attenuated cold-adapted H2N2 influenza virus vaccine candidates in non human primates.
    Broadbent AJ; Santos CP; Paskel M; Matsuoka Y; Lu J; Chen Z; Jin H; Subbarao K
    Vaccine; 2015 Jan; 33(1):193-200. PubMed ID: 25444799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus.
    Isakova-Sivak I; de Jonge J; Smolonogina T; Rekstin A; van Amerongen G; van Dijken H; Mouthaan J; Roholl P; Kuznetsova V; Doroshenko E; Tsvetnitsky V; Rudenko L
    PLoS One; 2014; 9(7):e102339. PubMed ID: 25058039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow-fill-seal device in adults: a randomized, active-controlled study*.
    Sheldon EA; Jeanfreau R; Sliman JA; Charenkavanich S; Rousculp MD; Dubovsky F; Mallory RM
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1142-50. PubMed ID: 23061976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
    Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE
    Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine.
    Babu TM; Levine M; Fitzgerald T; Luke C; Sangster MY; Jin H; Topham D; Katz J; Treanor J; Subbarao K
    Vaccine; 2014 Nov; 32(50):6798-804. PubMed ID: 25446831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
    Mallory RM; Yi T; Ambrose CS
    Vaccine; 2011 Jun; 29(26):4322-7. PubMed ID: 21513761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.